Neuroendocrinology News

Nearly 75% of adults with macroprolactinomas who discontinued cabergoline therapy after 5 years experienced disease remission for at least 12 months, study data show.

Annual health care costs and lost earnings in the United States from low-level but daily exposure to endocrine-disrupting chemicals exceeds $340 billion, suggesting a need for improved screening for these chemicals, study data show.

Adults with hypopituitarism and insufficient hormone levels should be treated by replacing hormones at levels close to the body’s natural patterns, according to a recent guideline from the Endocrine Society.

The Society for Endocrinology has issued clinical guidance for the treatment of five life-threatening endocrine emergencies, designed to help non-endocrinology specialists recognize these lesser-known conditions.

Exposure to steroids in utero in extremely premature infants may decrease the risk for certain birth defects and neurodevelopmental outcomes, study data show.

Surgery is an effective alternative to medical therapy for treatment of prolactinoma, with nearly three-quarters of microprolactinomas and one-third of macroprolactinomas resulting in long-term remission, study data show.

Traumatic brain injury has received increased attention in recent years primarily due to two highly visible groups affected by the condition. Soldiers returning from Iraq and Afghanistan have exhibited blast-related brain dysfunction in numbers greater than those of earlier conflicts, and professional football players have forced the NFL to recognize the chronic traumatic encephalopathy that follows some concussions.

Uncontrolled, persistent acromegaly is a strong predictor of incident type 2 diabetes, whereas disease diagnosis at an older age, and not disease activity, was associated with hypertension and major adverse cardiac events, according to a recent analysis.

Healio.com/Endocrinology recently launched In the Journals Plus, a new feature that will provide busy physicians with summaries of the top articles from leading journals in endocrinology.

The Mexican Acromegaly Registry, the first non-European registry of the disease and the largest such registry in the world, shows that the availability of resources influences treatment choices in different parts of Mexico, according to researchers.